Intervention
Urolithin A
Research Observatory
Evidence Update
Current evidence
Urolithin A was compared with placebo in separate older-adult and middle-aged trials of muscle and physical performance. Urolithin A did not significantly improve the older-adult trial's primary walking or maximal ATP endpoints; secondary muscle-endurance signals remain exploratory context. ATLAS reported hamstring-strength improvements, but its primary peak-power comparison was null and within-arm walking gains were not a confirmed between-arm benefit.
What changed
UA has secondary strength/endurance signals, but the reviewed primary functional comparisons did not demonstrate benefit.
What did not change
Mitochondrial target engagement is not proof of frailty prevention or longer life.
Why it matters
Prevents positive article titles from becoming a general functional-benefit claim.
Main limitation
Small selected cohort; secondary findings do not establish daily function, frailty prevention or longevity. The early phase-1 report supports short-term exposure/safety context, not efficacy. Secondary endpoints and multiple comparisons; within-arm improvement does not establish randomized treatment efficacy. The middle-aged cohort is not an identical replication of the older-adult trial.
Next proof
Independent adequately powered prespecified functional trial. Replicate the between-arm functional endpoint with multiplicity control.
Summary
Urolithin A was compared with placebo in separate older-adult and middle-aged trials of muscle and physical performance. Urolithin A did not significantly improve the older-adult trial's primary walking or maximal ATP endpoints; secondary muscle-endurance signals remain exploratory context. ATLAS reported hamstring-strength improvements, but its primary peak-power comparison was null and within-arm walking gains were not a confirmed between-arm benefit.
Intelligence Take
Prevents positive article titles from becoming a general functional-benefit claim.
Limitations
Small selected cohort; secondary findings do not establish daily function, frailty prevention or longevity. The early phase-1 report supports short-term exposure/safety context, not efficacy. Secondary endpoints and multiple comparisons; within-arm improvement does not establish randomized treatment efficacy. The middle-aged cohort is not an identical replication of the older-adult trial.